Pharmaceuticals & Biotech German Community

Item 1 – Business (what the company does) �Johnson & Johnson is a New Jersey–incorporated healthcare holding company with operating subsidiaries in virtually all countries and ~138,200 employees focused on human health and well‑being. �Operates in two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices and technologies).Read more

Perspectivas de Mercado Olhando para o horizonte de 2026 e além, a Bayer AG emerge como uma empresa em transição estratégica, navegando por desafios persistentes enquanto aposta em inovação e eficiência operacional para impulsionar uma recuperação sustentável. Após um 2025 marcado por declínios em lucros e pressões litigiosas, a companhia projeta um retorno ao crescimento de lucros a partir de 2026, impulsionado por um pipeline robusto em farmacêuticos, otimizações em Crop Science e uma reestruturação interna que visa economias significativas.Read more

Ecco cosa dicono gli utili di Novo Nordisk del Q4 2024 Nonostante le azioni si trovino ai minimi degli ultimi 15 mesi e il sentiment generale sia un po' ribassista, i dati del Q4 offrono spunti interessanti. Il colosso farmaceutico europeo ha registrato un incremento del 30,1% nelle vendite , raggiungendo 11,48 miliardi EUR, superando così le attese.Read more

Evotec is betting that using AI and massive biology datasets can make it a go-to partner for drugmakers, with its biologics unit and recurring service model driving faster growth and better pricing. But a slow funding market for biotech, tougher competition, and rapid shifts in AI could all stall that momentum.Read more

Bayer could get a bigger lift than many expect as newer medicines gain traction and farmers adopt more climate-ready crops and digital tools. But big legal claims, tougher rules, and heavy debt could still hold back the turnaround.Read more

Key Takeaways Focus on innovation, recurring revenue, and key partnerships across Life Science, Healthcare, and Electronics supports superior margin growth and earnings outperformance expectations. ESG leadership, portfolio streamlining, and exposure to emerging high-tech segments drive premium positioning, resilient capital structure, and durable, long-term shareholder value.Read more

Demand is shifting toward more complex injectable medicines, and SCHOTT Pharma is betting that bigger capacity and closer partnerships will make its drug packaging and delivery products harder to replace. The upside comes from higher-value, more sustainable offerings, but weak demand in some core lines, heavy spending, and leadership changes could slow progress.Read more

Gerresheimer is betting that a big acquisition and a push into more advanced drug packaging can lift profits as production upgrades come online. The catch is that integration hiccups, uneven cash flow, and weaker demand in one part of the business could get in the way.Read more

Heidelberg Pharma is betting on a new way to deliver cancer drugs that aims to punch through tough-to-treat tumors, with early trial results for its lead program drawing attention. The upside is big if its main study keeps going well and new drug candidates follow, but funding and setbacks in trials or manufacturing could quickly change the story.Read more